What We Do
Concept-to-Candidate Design – we create therapeutic formulas and novel hybrid molecules across pharmaceuticals, biologics, nutraceuticals, dietary supplements, and traditional/herbal medicine.
Future Focus
Expanding our expertise to new frontiers in healthcare technology.
Diagnostic Products
Leveraging our molecular design capabilities to create novel diagnostic tools for early and accurate disease detection.
Clinical Decision Support Software
Developing intelligent software to assist clinicians in making data-driven decisions for personalized patient care.
How We Work
- We design the molecular concept & therapeutic formula
- Contracted CROs execute full drug-discovery workflow (in-silico → in-vitro → in-vivo → clinical)
- CROs formulate into oral, injectable, topical, or specialized dosage forms
- We receive results; no IND-enabling packages generated internally
Current Partnership
We have partnered with Web3/DeSci projects to get us milestone-based funding per each drug discovery phase.
Partnering Models
- Immunomodulator contracts and pays the CRO per discovery phase (in-silico, in-vitro, or in-vivo). A single CRO engagement can cover multiple drug candidates (even across different therapeutic areas) as long as every candidate and every phase is explicitly scoped and billed separately—no blanket retainers, no hidden mark-ups.
- IP ownership: remains exclusively ours to license out.
Contact Us
We're ready to collaborate. Reach out to the right team to get started.